Autolus Therapeutics plc
Ownership
Ownership Structure
Who owns Autolus Therapeutics plc (AUTL)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 38.7% of the shares are freely tradable; institutional investors hold 64.3%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Mak Capital One LLC | 12.63 | 33,621,487 | +12.1 | 03/31/2026 |
| Blackstone Inc | 7.70 | 20,485,611 | +0.0 | 03/31/2026 |
| Syncona Portfolio Ltd. | 6.25 | 16,640,720 | +0.0 | 06/30/2026 |
| Armistice Capital, LLC | 5.94 | 15,800,000 | -9.7 | 03/31/2026 |
| Polygon Management Ltd | 3.57 | 9,500,000 | +0.0 | 06/30/2026 |
| Schroder Investment Management Group | 2.94 | 7,833,282 | -17.5 | 06/30/2026 |
| Frazier Life Sciences Management, L.P. | 1.67 | 4,447,910 | -3.8 | 03/31/2026 |
| BNP Paribas Investment Partners SA | 1.26 | 3,361,156 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| International Biotechnology Ord | 2.45 | 6,531,015 | -9.5 | 08/31/2026 |
| AXA Framlington Health Fund - R Income | 1.26 | 3,361,156 | +0.0 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Piccina Cintia | U.S. CCO & Country Gen Manager | 13,287 | 25,245 $ | Sep 2, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Piccina Cintia | U.S. CCO & Country Gen Manager | Sell | 6,713 | 2.34 | 15,682 |
| Sep 1, 2026 | Piccina Cintia | U.S. CCO & Country Gen Manager | Other | 20,000 | 2.35 | 47,000 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.